Introduction
Systemic lupus erythematosus (SLE) is a complex heterogeneous disease which follows an unpredictable relapsing remitting course. With the advent of earlier detection, rationalization of immunosuppressive regimens and advances in renal supportive therapy such as dialysis and renal transplantation, the prognosis and survival of patients with SLE has significantly improved over recent decades. In the past the major cause of death in SLE was uncontrolled disease activity [Merrell and Shulman, 1955] . Currently, atherosclerotic complications, malignancy, infection and to a lesser degree active disease are the chief causes of mortality in SLE [Bernatsky et al. 2006 ].
There remains an unmet clinical need in SLE, particularly in lupus nephritis and neuropsychiatric disease resistant to conventional immunosuppressive therapies. Recurrent flares of lupus nephritis activity are associated with poor longterm renal outcomes [Moroni et al. 1996; Mosca et al. 2002] . Renal damage is known to be the overall most important predictor of mortality in SLE patients [Danila et al. 2009 ]. Overreliance on corticosteroids remains an issue in the management of SLE and contributes to long-term damage accrual and mortality [Bruce et al. 2014 ].
B-cell depletion therapies

Rituximab
The predominant B-cell depleting therapy currently used in the clinical management of SLE is rituximab, a chimeric monoclonal antibody which selectively targets B cells with the surface marker CD20. Rituximab, while widely used, particularly in SLE patients with resistant disease, remains unlicensed. Rituximab has been approved for the management of other rheumatic diseases such as rheumatoid arthritis and antineutrophil cytoplasmic antibody (ANCA) associated vasculitis on the basis of positive data from randomized controlled trials [Cohen et al. 2006; Stone et al. 2010; Jones et al. 2010] . Several case series and open label trials of rituximab in SLE have yielded encouraging results [Lu et al. 2009; Terrier et al. 2010; Catapano et al. 2010; Diaz-Lagares et al. 2012; Pepper et al. 2009 ]. However, two randomized controlled trials of rituximab in nonrenal SLE (EXPLORER) and in lupus nephritis (LUNAR) failed to achieve their primary endpoints [Merrill et al. 2010b; Rovin et al. 2012] . It should be noted that patients in both the LUNAR and EXPLORER studies were taking significant amounts of background immunosuppression, including corticosteroid, which may in part account for the poor study outcomes highlighting the importance of study design in clinical trials of SLE.
A recent prospective observational study of rituximab as part of a corticosteroid sparing regimen in lupus nephritis patients has shown promising results [Condon et al. 2013 ]. This has led to a multicentre randomized controlled trial (RITUXILUP) with rituximab as induction therapy followed by maintenance mycophenolate mofetil. This study is ongoing, the results of which are keenly anticipated [ClinicalTrials.gov identifier: NCT01773616].
Another ongoing trial of rituximab in SLE is the RING study (Rituximab for Lupus Nephritis With Remission as a Goal), which is an openlabel, multicentre trial aiming to determine the efficacy of rituximab in achieving complete renal remission in lupus nephritis patients with persistent proteinuria despite a minimum of 6 months of standard immunosuppression [ClinicalTrials. gov identifier: NCT01673295].
From a safety point of view while rituximab is generally safe and well tolerated, infusion reactions, allergic or anaphylactic reactions, severe or recurrent infections and progressive multifocal leucoencephalopathy (PML) have been reported in rituximab treated SLE patients [Diaz-Lagares et al. 2011; Calabrese and Molloy, 2008] . The US Food and Drug Administration (FDA) recently issued a warning regarding the possibility of hepatitis B reactivation in patients who have received rituximab [Burton et al. 2015] .
Epratuzumab
Epratuzumab is a monoclonal antibody targeting anti-CD22, a cell surface marker on transitional B cells and naïve mature B cells causing moderate B-cell depletion via antibody-dependent cellular cytotoxicity (ADCC). Epratuzumab has been shown to inhibit the proliferation of B cells from SLE patients but not normal B cells under all culture conditions [Jacobi et al. 2008] . The therapeutic activity of epratuzumab may not result completely from B-cell depletion. In addition, epratuzumab mediates the Fc (fragment, crystallizable) /Fc receptor (FcR) dependent membrane transfer from B lymphocytes to effector cells via trogocytosis, resulting in reduction of multiple B-cell receptor modulators including CD22, CD19, CD21 and CD79b, as well as important adhesion molecules [Rossi et al. 2013 .
The first open-label study of epratuzumab treated 14 SLE patients with moderately active disease and showed that total British Isles Lupus Assessment Group (BILAG) scores decreased by ⩾50% in all participants at some point during the course of the study. The drug was well tolerated with no evidence of immunogenicity or significant changes in T cells, immunoglobulins or autoantibody levels [Dorner et al. 2006 ].
The ALLEVIATE studies of epratuzumab in moderate-to-severe active SLE were discontinued prematurely because of an interruption in drug supply. Exploratory pooled analyses of the trials showed improved BILAG scores at week 12 in 44.1% and 20.0% of epratuzumab 360 and 720 mg/m 2 , respectively, compared with 30.0% for placebo. Adverse events were similar between groups .
The phase IIb EMBLEM study of epratuzumab in 227 patients with moderate-to-severe active SLE used a novel composite endpoint, the BILAG-based Combined Lupus Assessment (BICLA) at 12 weeks. The proportion of responders was higher in epratuzumab treated groups than with placebo. Adverse events were not significantly higher in those who received epratuzumab and no significant reductions in immunoglobulin levels were seen [Wallace et al. 2014a ].
Phase III trials examining the efficacy and safety of epratuzumab in moderate to severe SLE are ongoing [ClinicalTrials.gov identifier: NCT01262365, NCT01261793].
Inhibitors of the BLyS/APRIL pathway B lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand) are part of the tumour necrosis factor (TNF) ligand superfamily and play important roles in modulating the innate immune system in the regulation of B-cell activation. A complex interplay exists between BLyS/ APRIL and their receptors. BLyS is also known as B-cell activating factor (BAFF) and its functions include induction of B-cell proliferation, differentiation and immunoglobulin secretion [Moore et al. 1999; Schneider et al. 1999] . BLyS exists in both membrane bound and soluble forms and is expressed by monocytes, macrophages and dendritic cells. BLyS can bind to three receptors, all of which are expressed by B cells, including TACI (TNF transmembrane activator and calcium modulator and cyclophilin ligand interactor), BCMA (B lymphocyte maturation antigen) and BR3 (BAFF/BLyS receptor 3) [Gross et al. 2000; Thompson et al. 2001] . A further TNF superfamily member, APRIL, can also bind TACI and BCMA with biologic functions similar to BLyS. APRIL binds with higher affinity to TACI than BLyS. BLyS and APRIL may circulate as heterodimer complexes with various combinations of the two cytokines; however, the exact role of these heterodimers in the context of SLE is as yet unknown [Stohl, 2010] . Plasma and peripheral blood leukocyte mRNA BLyS levels correlate with disease activity and autoantibody titres in SLE patients [Cheema et al. 2001; Petri et al. 2008; Collins et al. 2006 ]. BLyS levels are also elevated in other autoimmune diseases such as rheumatoid arthritis and Sjögren's syndrome [Mariette et al. 2003 ].
Belimumab
Belimumab is a monoclonal antibody targeting BLyS and has been studied in two large randomized controlled trials in SLE. The Belimumab International SLE Study (BLISS-52) phase III trial enrolled 865 SLE patients from central and eastern Europe, Latin America and Asia Pacific [Navarra et al. 2011 ]. The Belimumab International SLE Study (BLISS-76) enrolled 819 SLE patients from North America, western and central Europe [Furie et al. 2011] . Both of these studies excluded SLE patients with active lupus nephritis or neuropsychiatric disease.
The primary clinical endpoint in these studies was improvement in the SLE responder index (SRI). SRI clinical response is defined as: ⩾4 points reduction in the Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA) -Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score; no new BILAG A organ domain score and no new >1 new B organ domain score; and <0.3 increase in the Physicians Global Assessment (PGA) or no worsening of PGA compared with baseline.
The SRI clinical response rate at week 52 in the BLISS-52 study was 58% in belimumab 10 mg/kg with standard therapy treated patients and 51% in belimumab 1 mg/kg with standard therapy treated patients compared with 44% in those who received placebo and standard therapy (p = 0.0006, p = 0.013 respectively) [Navarra et al. 2011 ].
The SRI clinical response rate at week 52 in the BLISS-76 study was 43% in belimumab 10 mg/ kg with standard therapy treated patients and 41% in belimumab 1 mg/kg with standard therapy treated patients compared with 34% in placebo and standard therapy treated patients (p = 0.021 and p = 0.1, respectively) [Furie et al. 2011 ]. There was no significant difference in SRI clinical response rates between the placebo and belimumab treated patients at week 76 of the BLISS-76 study.
Combining data from the BLISS trials, greater clinical efficacy was seen in SLE patients who were serologically more active, that is those who were anti double stand DNA antibody positive, and were hypocomplementemic. In addition, patients with higher clinical disease activity as defined as a SELENA-SLEDAI score >10 had a more efficacious response to belimumab [van Vollenhoven et al. 2012] .
Following the BLISS-52 and BLISS-76 trials, the FDA and the European Medicines Agency (EMA) approved belimumab (10 mg/kg) for use in autoantibody positive SLE with moderate-to-severe disease activity, with the exception of patients with active lupus nephritis or central nervous system (CNS) disease. Thus belimumab became the first drug in over 50 years to be licensed for the treatment of SLE.
The potential role of belimumab in lupus nephritis, neuropsychiatric disease and in combination with other biologic agents and cyclophosphamide has yet to be established and clinical trials addressing these issues are ongoing. The BLISS-LN phase III study has been devised to evaluate the efficacy and safety of belimumab plus standard of care versus placebo plus standard of care in active lupus nephritis, and is actively recruiting patients [ClinicalTrials.gov identifier: NCT01639339]. BLyS levels are known to increase post rituximab therapy in SLE patients and an interesting approach may be to give both therapies sequentially [Cambridge et al. 2008] . A trial examining sequential rituximab and belimumab in lupus nephritis has been proposed but is not yet open for recruitment. The study will compare the combination of rituximab and cyclophosphamide (at weeks 0 and 2) and a combination of rituximab and cyclophosphamide followed by belimumab (at weeks 4, 6 and 8, and every 4 weeks to week 48) [ClinicalTrials.gov identifier: NCT02260934]. An exploratory analysis of the BLISS studies showed lower clinical efficacy of belimumab in SLE patients of African ancestry. The EMBRACE study, a phase III/IV randomized, controlled trial of belimumab in SLE patients of African descent is actively recruiting and addresses this important issue [ClinicalTrials.gov identifier: NCT01632241]. A phase III trial of subcutaneously administered belimumab (BLISS-SC) in SLE patients is also ongoing [ClinicalTrials.gov identifier: NCT01484496].
Overall, belimumab has been found to be safe and well tolerated, although an increased susceptibility to common infections such as bronchitis, pharyngitis, cystitis and viral gastroenteritis has been reported. No specific opportunistic infections or patterns of infection have been associated with belimumab treatment to date. Two cases of PML have been reported in the medical literature in belimumab treated patients [Fredericks et al. 2014] .
Tabalumab
Tabalumab is a humanized monoclonal antibody targeting membrane bound and soluble BLyS. Recently, tabalumab failed to meet its primary endpoint of significant improvement in SRI in one of two large phase III trials (ILLUNINATE 1 and 2) and development of the drug has been discontinued [Eli Lilly and Company, 2014] .
Atacicept
Atacicept is a fully humanized, recombinant TACI receptor fusion protein that targets the BLyS/ APRIL axis [Dillon et al. 2010] . A phase I trial of atacicept in SLE patients showed dose-dependent reductions in immunoglobulin levels and in mature and total B cells [Dall'era et al. 2007 ]. The APRIL-LN phase II/III study of atacicept in active lupus nephritis was prematurely terminated after recruitment of only six patients due to unexpected but significant reductions in immunoglobulin levels and development of serious infections including haemophilus influenza pneumonia, legionella pneumonia and bacillus bacteraemia [Ginzler et al. 2012 ]. However, it should be noted that the reduction in the immunoglobulin levels took place when the study patients were given mycophenolate mofetil, prior to the introduction of atacicept. A further double-blind placebo controlled study of atacicept in moderate-to-severe nonrenal lupus (APRIL-SLE) was terminated early due to two unexpected deaths. One of these patients died from acute respiratory failure secondary to alveolar haemorrhage. This patient was known to have an overlap syndrome with features of scleroderma. The second patient died from pneumococcal pneumonia and alveolar haemorrhage secondary to lupus . A further phase II trial examining the efficacy and safety of atacicept in SLE (ADDRESS II) is ongoing [ClinicalTrials. gov identifier: NCT01972568].
Therapies targeting T-B lymphocyte interactions
Abatacept Abatacept is a fusion protein comprised of cytotoxic T-lymphocyte antigen (CTLA4) combined with the Fc portion of human IgG1 (CTLA4-Ig). Blockade of costimulatory interactions between T and B cells may result in the induction of immunological tolerance. CD28 is a T-cell costimulatory ligand that interacts with the receptors B7-1 (CD80) and B7-2 (CD86). CTLA4 on activated T cells interacts with B7 with greater affinity than CD28, resulting in a negative feedback loop that inhibits T-cell activation [Scheipers and Reiser, 1998; Reiser and Stadecker, 1996; Brunet et al. 1987 ]. In murine models of lupus nephritis, the combination of CTLA-4-Ig and cyclophosphamide has been shown to significantly reduce proteinuria, autoantibody levels and increase longevity [Daikh and Wofsy, 2001; Cunnane et al. 2004; Finck et al. 1994] .
A phase II trial of abatacept in nonrenal SLE patients failed to meet its primary endpoint of reduction in new BILAG A/B flares [Merrill et al. 2010a ], but did show improvements in fatigue and quality of life measures. A phase II/ III trial of abatacept in proliferative lupus nephritis (classes III and IV) failed to meet its study endpoint of complete renal response. However, a very strict end definition of complete renal response was used in the study and was defined as achieving a glomerular filtration rate within 10% of the pre flare/baseline value, urinary protein creatinine ratio <0.26 mg/mg and an inactive urinary sediment . A re-analysis of the same study data was undertaken using outcome measures from the LUNAR and ALMS trials and showed a positive outcome in favour of abatacept therapy [Wofsy et al. 2013] . Overall, this emphasizes the importance of study design and standardization of outcome measures in SLE clinical trials. A further phase II multicentre trial of abatacept plus cyclophosphamide versus cyclophosphamide alone in the lupus nephritis is ongoing [ClinicalTrials.gov identifier: NCT00774852].
Targeting type I interferon
Type I interferon family members play a major role in innate immunity and host viral defence. Several lines of evidence link type I interferon to the pathogenesis of SLE. It is well established that patients with SLE have high serum levels of interferon-α [Hooks et al. 1979; Ytterberg and Schnitzer, 1982] . It has also been noted that viral hepatitis and oncology patients receiving interferon-α therapy develop autoimmune side effects [Ronnblom et al. 1990 [Ronnblom et al. , 1991 Kalkner et al. 1998 ].
Serum interferon-α levels have been shown to correlate with disease activity and severity in SLE patients [Bengtsson et al. 2000 ]. While not all SLE patients have raised serum interferon-α, the majority have an interferon gene expression signature in peripheral blood mononuclear cells (PBMCs), particularly in the early stages of their disease [Bennet et al. 2003; Baechler et al. 2003 ]. Gene expression microarray profiles demonstrate upregulation of interferon-inducible genes, particularly in those with severe SLE manifestations such as lupus nephritis and neuropsychiatric disease.
Additional evidence of the contribution of type I interferon to lupus pathogenesis is provided by the regularity with which variants in genes involved in interferon signalling pathways are identified in SLE genome wide association studies (GWAS) including IRF5, IRF7, IRF8, STAT4, TYK2 and IFIH1. Furthermore, there is a strong link between monogenic causes of SLE and interferonopathies such as Aicardi-Goutieres syndrome [Lee-Kirsch et al. 2007; Rice et al. 2013 Rice et al. , 2014 .
Sifalimumab
Sifalimumab, a fully human anti-interferon α monoclonal antibody, was shown in a phase I study to induce a dose-dependent inhibition of type I interferon-induced mRNAs in whole blood of moderately active SLE patients. No significant increase in viral infections was seen and disease activity generally improved [Merrill et al. 2011] . A further phase I dose-escalation study of sifalimumab in adult patients with moderate-toseverely active SLE showed good safety and tolerability and inhibition of the type I interferon gene signature particularly in those with a high baseline signature .
A phase IIb trial evaluating the efficacy and safety of sifalimumab in SLE achieved its primary end points using the SRI(4) and the more stringent SRI(6-8). Organ specific endpoints were also significantly improved with sifalimumab including the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), 28 joint count and FACIT-Fatigue score. There was a minor increase in viral infections, particularly herpes zoster, in the sifalimumab treated group [Khamashta et al. 2014] .
Rontalizumab
Rontalizumab, a recombinant humanized monoclonal antibody to interferon-α, was shown to be safe and well tolerated in a phase I, dose-escalation study in mildly active SLE patients [McBride et al. 2012] . However, a further study did not meet its primary end point of significant improvement in SRI and rontalizumab has been withdrawn from further development.
Anifrolumab
A third agent targeting type I interferon is anifrolumab, an anti-interferon-α receptor 1 antibody [Peng et al. 2015] . Two phase II randomized, open label studies of sifalimumab (n = 30) and anifrolumab (n = 17) have been undertaken in Japanese patients with SLE [Morehouse et al. 2014] . Anifrolumab had a more significant and more sustained impact on the interferon gene signature as compared to sifalimumab [Morehouse et al. 2014] . Anifrolumab is now being brought forward to phase III studies.
Targeting interleukin-6
Tocilizumab The pleiotropic cytokine interleukin-6 (IL-6) has both pro-inflammatory and anti-inflammatory effects. In murine models of lupus nephritis, exogenous IL-6 increases autoantibody titres and accelerates progression of renal disease [Ryffel et al. 1994; Yang et al. 1998 ]. Giving an IL-6 monoclonal antibody was shown to reduce anti-dsDNA titres, proteinuria and mortality in these models [Liang et al. 2006; Mihara et al. 1998 ]. IL-6 levels correlate with clinical activity and anti-dsDNA antibody titres in SLE patients [Chun et al. 2007; Linker-Israeli et al. 2001] . Urinary excretion of IL-6 is increased during active proliferative lupus nephritis and levels subsequently decline following immunosuppression with cyclophosphamide [Peterson et al. 1996; Tsai et al. 2000 ].
Tocilizumab is a fully humanized monoclonal antibody against the IL-6 receptor and prevents binding of IL-6 to both its membrane bound and soluble forms. A phase I trial of tocilizumab in SLE showed good tolerance to the drug with reduction in active urinary sediment and autoantibody titres [Illei et al. 2010] . A further study of tocilizumab in 15 SLE patients with mild-tomoderate disease activity showed reduced activated T and B cells [Shirota et al. 2013] . A number of cases reports are to be found in the literature suggesting efficacy of tocilizumab in severe refractory lupus including resistant haematologic manifestations and serositis [Kamata and Minota, 2012; Garcia-Hernandez et al. 2012; Makol et al. 2012; Adler et al. 2013] . Further studies are needed to define the role of tocilizumab in the treatment of SLE.
A further monoclonal antibody (PF-04236921) has been studied in 183 patients with active SLE and has been shown to reduce severe flares. The drug was given subcutaneously at 10, 50 and 200 mg doses. The safety profile with 10 and 50 mg doses appeared acceptable, but dosing with 200 mg was terminated due to safety concerns given that there were 3 deaths including cardiorespiratory arrest, urosepsis with pulmonary embolism and disseminated tuberculosis [Wallace et al. 2014b ].
Other biologic agents in development
Further to the biologic agents discussed in this review, a number of other therapeutic targets have been identified on the basis of our increased knowledge of the aetiopathogenesis of SLE and are in early stages of development. Potential targets include toll-like receptor pathways, TWEAK (TNF-related weak inducer of apoptosis), a mediator of nuclear factor-κB (NF-κB) pathway activation and the tyrosine kinase SYK.
A novel strategy in the treatment of SLE is the concept of resetting the autoreactivity of the immune system by using tolerogenic peptides. One such agent is Lupuzor, which has been studied in a phase II trial of 149 SLE patients, shown to be efficacious in terms of SRI and was well tolerated [Zimmer et al. 2013 ].
Bortezomib, a proteasome inhibitor approved for use in multiple myeloma, has been reported to be effective in murine models of lupus nephritis and in refractory cases of human SLE [Hainz et al. 2012; Wang et al. 2015; Alexander et al. 2015; Quartuccio et al. 2014] . The proteasome regulates protein expression and function by degradation of ubiquitinated proteins and inhibition of this process may result in programmed cell death in plasma cells. Studies to date in SLE have had a relatively short duration of clinical follow up and long-term safety data of bortezomib in autoimmune diseases have yet to be seen. Table 1 shows pivotal trials of biologic therapies in SLE.
Treat-to-target in SLE
The concept of treating-to-target (T2T) has been successfully applied to many diseases including diabetes mellitus, hypertension and hypercholesterolaemia, and more recently to rheumatoid arthritis. In 2014, a task force of specialists involved in the care of SLE patients including those in rheumatology, nephrology, dermatology and immunology developed key recommendations for T2T in SLE (T2T/SLE) [van Vollenhoven et al. 2014] . Prominent features of the T2T/SLE recommendations include early identification of lupus nephritis, targeting remission, minimizing exposure to corticosteroids, optimal management of co-existent antiphospholipid syndrome, prevention of long-term damage accrual and improving quality of life in SLE patients. It is hoped that the T2T/SLE recommendations will led to improved care for SLE patients and provide useful guidance for those involved in their clinical management. However, targeting some SLE manifestations may be more easily quantified than others such as lupus nephritis compared with CNS manifestations which may make T2T/SLE challenging. Table 2 summarizes T2T in SLE.
Conclusion and future perspectives
Overall, physicians involved in the management of SLE should be enthusiastic given the array of promising new therapies becoming available for lupus disease control and further therapies yet to emerge. The clinical implications of biologic therapies in the management of SLE are, on the whole, positive. The advent of more targeted therapies should, in theory, increase our ability to control disease activity in SLE patients and minimize unnecessary toxicity.
However, a number of questions remain unanswered as to the optimal use of biologics in a complex and heterogeneous disease such as SLE. It is highly unlikely that one biologic agent will successfully treat all disease manifestations of lupus in all patients. Diagnostic and prognostic strategies will need to be developed to determine which biologic therapy is likely to be efficacious in which SLE patient and at what time point in their disease course.
Currently, biologic therapies are primarily used in clinical scenarios where SLE patients remain resistant to conventional immunosuppressive agents. Perhaps the ideal use of biologics in SLE is early in the disease course akin to anti-TNF therapy in rheumatoid arthritis. Ongoing clinical trials of rituximab and belimumab may help clarify this issue.
Belimumab is now licensed for use in the treatment of SLE and, on the basis of currently available evidence from the BLISS-52 and BLISS-76 studies, physicians are most likely to use belimumab in addition to standard therapy in patients with musculoskeletal and mucocutaneous manifestations of SLE. Further studies are needed to clarify the role of belimumab in patients with severe lupus nephritis and severe CNS disease.
Clinical trial design and standardization of study outcomes are of utmost importance as exemplified by the LUNAR and EXPLORER trials of rituximab where high background levels of corticosteroids and immunosuppression may have hampered interpretation of results, and in the case of abatacept in lupus nephritis with varying study outcomes depending on which definition of complete renal response was used.
The long-term toxicity of biologic agents in SLE patients is also unknown. Rituximab has the most accumulated data of long-term patient exposure given its use in the treatment of lymphoma, but for many of these other agents there is limited long-term safety data. Biologics registries both on a nation and international basis will be crucial in accumulating and collating these important data.
Issues with regulation and the cost of new drugs remain significant stumbling blocks preventing patients from gaining access to these medications and further challenges lie ahead. The future advent of biosimilars may reduce cost and increase availability of such agents; however, caution must be exercised that these agents are as efficacious and safe as the original compounds. Finck, B., Linsley, P. and Wofsy, D. (1994) Treatment of murine lupus with CTLA4Ig. Science 265: 1225-1227.
